Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SETDB1 | Q15047 | 1/20 | 0.55 |
| ▸ | HTR1A | P08908 | 4/20 | 0.50 |
| ▸ | DRD2 | P14416 | 2/20 | 0.50 |
| ▸ | DRD3 | P35462 | 2/20 | 0.50 |
| ▸ | DRD4 | P21917 | 1/20 | 0.50 |
| ▸ | HTR2A | P28223 | 1/20 | 0.50 |
| ▸ | HTR2C | P28335 | 1/20 | 0.50 |
| ▸ | BRD9 | Q9H8M2 | 1/20 | 0.50 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.49 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.49 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.49 |
| ▸ | ADRB1 | P08588 | 3/20 | 0.49 |
| ▸ | HTR6 | P50406 | 2/20 | 0.47 |
| ▸ | MC4R | P32245 | 1/20 | 0.45 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.44 |
| ▸ | HTR3B | O95264 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | HTR3A | P46098 | 1/20 | 0.44 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.44 |
| ▸ | HTR3C | Q8WXA8 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL8336633 | 0.99 | SETDB1 (0.53) | SETDB1HTR1ADRD2DRD3DRD4 | |
| SCHEMBL14355981 | 0.87 | HTR1A (0.52) | SETDB1HTR1ADRD2DRD3DRD4 | |
| SCHEMBL14355983 | 0.83 | HTR6 (0.55) | HTR1ADRD2DRD3DRD4HTR2A | |
| SCHEMBL22547353 | 0.82 | GUSB (0.46) | SETDB1HTR1AHTR2AHTR2CSLC6A4 | |
| SCHEMBL16814964 | 0.80 | HTR1A (0.55) | HTR1ADRD2DRD3DRD4HTR2A | |
| SCHEMBL31561598 | 0.80 | HTR1A (0.73) | HTR1ADRD2DRD3DRD4HTR2A | |
| SCHEMBL335802 | 0.80 | HTR1A (0.73) | HTR1ADRD2DRD3DRD4HTR2A | |
| SCHEMBL28078181 | 0.80 | HTR1A (0.73) | HTR1ADRD2DRD3DRD4HTR2A | |
| SCHEMBL20883683 | 0.79 | HTR6 (0.37) | SETDB1HTR1ADRD2DRD3DRD4 | |
| SCHEMBL7956809 | 0.79 | SETDB1 (0.53) | SETDB1HTR1ABRD9MC4RCYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7291619-B2 | Melanocortin receptor agonists | ELI LILLY AND COMPANY (US) | 2007-11-06 | — | — | US | disclosed |
| US-7291619-B2 | Melanocortin receptor agonists | ELI LILLY AND COMPANY (US) | 2007-11-06 | — | — | US | disclosed |
| EP-1603912-B1 | SUBSTITUTED PIPERIDINE AND PIPERAZINE DERIVATIVES AS MELANOCORTIN-4 RECEPTOR MODULATORS | SANTHERA PHARMACEUTICALS CH (CH) | 2007-07-18 | — | — | EP | disclosed |
| US-20060241123-A1 | Substituted piperidine and piperazine derivatives as melanocortin-4 receptor modulators | SANTHERA PHARMACEUTICALS (SCHWEIZ) GMBH (CH) | 2006-10-26 | — | — | US | disclosed |
| EP-1603912-A1 | SUBSTITUTED PIPERIDINE AND PIPERAZINE DERIVATIVES AS MELANOCORTIN-4 RECEPTOR MODULATORS | Santhera Pharmaceuticals (Schweiz) GmbH (CH) | 2005-12-14 | — | — | EP | disclosed |
| WO-2004083209-A1 | SUBSTITUTED PIPERIDINE AND PIPERAZINE DERIVATIVES AS MELANOCORTIN-4 RECEPTOR MODULATORS | SANTHERA PHARMACEUTICALS (SCHWEIZ) GMBH (CH) | 2004-09-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060241123-A1 | Substituted piperidine and piperazine derivatives as melanocortin-4 receptor modulators | MC4R, MC5R, MC3R | SETDB1 2515/4885HTR1A 72/4885DRD2 134/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.